February 28, 2022Open Access

Efficacy of Immune Checkpoint Inhibitors in Patients With EGFR Mutated NSCLC and Potential Risk Factors Associated With Prognosis: A Single Institution Experience

Key Points

Key points are not available for this paper at this time.

Abstract

We found that combination regimen of immunotherapy plus chemotherapy plus antiangiogenetic agents may yield longer survival in patients with EGFR mutated NSCLC. We also found that patients with longer PFS-TKI, concurrent extracranial radiotherapy and higher BMI may benefit more from immunotherapy.

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Bai et al. (Mon,) studied this question.

synapsesocial.com/papers/69d80cd866a29169b4bedea2 https://doi.org/https://doi.org/10.3389/fimmu.2022.832419

Demander à l'IA

Bookmark

View Full Paper